 | |
| Legal status | |
|---|---|
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C23H26FN3O2 |
| Molar mass | 395.478 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
ADB-FUBIATA (AD-18,FUB-ACADB,ADB-FUBIACA) is asynthetic cannabinoid compound first identified in 2021. It is closely related in structure to the older compoundADB-FUBICA but with theamide linker group extended by the addition of amethylene bridge. It started to be sold as an ingredient in grey-market synthetic cannabis blends following the introduction of legislation in China which for the first time introducedgeneral controls on various classes of synthetic cannabinoids,[2] but did not encompass compounds where the linker group had been extended in this fashion. ADB-FUBIATA has many times lower affinity forcannabinoid receptors than ADB-FUBICA with an EC50 of only 635 nM at CB1, but retains full agonist activity at this target, while being practically inactive at CB2.[3][4]
In the United States ADB-FUBIATA is unscheduled at the federal level as of May 22, 2023 but may be considered under thefederal analogue act if sold for human consumption. North Dakota has placed ADB-FUBIATA into Schedule I on 04/27/2023.[5]
 | Thiscannabinoid related article is astub. You can help Wikipedia byexpanding it. |
